← Back to Search

Loop Diuretic

Furosemide Injection for Cardio-Renal Syndrome

N/A
Recruiting
Led By Christopher W McIntyre, MD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients from visit 1 with diuretic resistance
Clinico-pathological diagnosis of heart failure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through mri, an average of 60 minutes
Awards & highlights

Study Summary

This trialaims to investigate the use of MRI to measure kidney salt content & observe diuretic response in patients with heart failure & kidney disease, to predict diuretic resistance & improve treatment.

Who is the study for?
This trial is for adults over 18 with a certain level of kidney function, diagnosed with heart failure and experiencing fluid overload despite taking diuretics like furosemide. They must be able to consent and not have conditions that exclude them from MRI scans or other specific health issues.Check my eligibility
What is being tested?
The study tests if measuring kidney sodium content using MRI can predict how well patients with heart failure and kidney disease respond to diuretics. It compares this response in those resistant to diuretics before and after an extra dose of the medication.See study design
What are the potential side effects?
Potential side effects include dehydration, electrolyte imbalances (like low potassium), low blood pressure, dizziness, increased urination, potential allergic reactions to the drug or contrast agent used in MRI.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My water pills are not working as expected.
Select...
I have been diagnosed with heart failure.
Select...
I am 18 years old or older.
Select...
My kidney function is at a safe level for the trial.
Select...
I have been on water pills for at least a week.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through mri, an average of 60 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and through mri, an average of 60 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Medullary sodium concentration
Secondary outcome measures
Change in corticomedullary sodium gradient
Change in medullary sodium concentration
Kidney
+6 more

Side effects data

From 2017 Phase 4 trial • 57 Patients • NCT01441245
27%
rehospitalization for all cardiovascular causes
20%
death
100%
80%
60%
40%
20%
0%
Study treatment Arm
cIV Group
iIV Group

Trial Design

1Treatment groups
Experimental Treatment
Group I: Furosemide InjectionExperimental Treatment1 Intervention
Patients with diuretic resistance: The presence of diuretic resistance, defined as having clinical signs of fluid overload despite diuretic therapy (this information is routinely collected at each clinical visit). "Fluid overload" is defined as the presence of at least two of the following clinical features: Peripheral or sacral oedema Jugular venous distension ≥ 7 cm Radiographic pulmonary oedema or pleural effusion Enlarged liver or ascites Pulmonary rales, paroxysmal nocturnal dyspnoea, or orthopnoea Point of Care UltraSound (POCUS) evidence of congestion. Inferior Vena Cava diameter >2.5 cm and/or failure to collapse at least 50% with sharp inspiration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Furosemide
FDA approved

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
659 Previous Clinical Trials
413,682 Total Patients Enrolled
Christopher W McIntyre, MDPrincipal InvestigatorWestern University
4 Previous Clinical Trials
122 Total Patients Enrolled

Media Library

Furosemide Injection (Loop Diuretic) Clinical Trial Eligibility Overview. Trial Name: NCT04170855 — N/A
Cardio-Renal Syndrome Research Study Groups: Furosemide Injection
Cardio-Renal Syndrome Clinical Trial 2023: Furosemide Injection Highlights & Side Effects. Trial Name: NCT04170855 — N/A
Furosemide Injection (Loop Diuretic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04170855 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Under what circumstances might this intervention be beneficial?

"This therapy has been proven to successfully treat congestive heart failure, peripheral edema, and pulmonary congestion."

Answered by AI

What is the uppermost cap of participants in this research endeavor?

"Indeed, the information available on clinicaltrials.gov denotes that this medical trial is currently recruiting candidates. The research was first made public on October 20th 2020 and has been revised as recently as December 21st 2022. 50 subjects are needed to be recruited from only one location for this study."

Answered by AI

Are there any prior explorations of this therapeutic approach?

"At this moment, 12 trials for the medication are under way. Three of these studies have reached Phase 3 status. Most clinical trials occur in London, Ontario but there are 34 participating sites across the country."

Answered by AI

Are there vacancies in this research program for participants?

"Yes, according to clinicaltrials.gov this research is currently seeking participants for the study which was initially posted on October 20th 2020 and updated as recently as December 21st 2022."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Kidney Sodium Content in Cardiorenal Patients
Chris McIntyre 2020. "Kidney Sodium Content in Cardiorenal Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04170855.
~8 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top